Schott Pharma stock reports 8.3 percent Q3 growth

Published on 10/05/2026 at 19:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Schott Pharma stock points to EUR 281.8 million Q3 revenue for the period ended June 30, 2026. The company targets a 27%-28% EBITDA margin for fiscal 2026.

Schwarzweiß-Reportagefoto einer Ampullen-Abfüllanlage mit Techniker — SCHOTT Pharma (DE000A3ENQ51) dokumentiert eine Ampullen-Abfüllanlage in dramatischer Schwarzweiß-Reportagefotografie mit einem Reinraumtechniker davor, Illustration mit AI erstellt.

Schott Pharma (ISIN DE000A3ENQ51) was last at EUR 24.70 on Xetra on October 5, 2026, while its latest quarter delivered EUR 281.8 million in revenue. According to Yahoo Finance, the company reported 8.3 percent constant-currency growth in Q3 fiscal 2026.

Revenue growth reaches 8.3 percent

The quarter ended June 30, 2026, showed 10 percent reported revenue growth, according to Yahoo Finance. Drug Containment Solutions revenue rose to EUR 158.9 million, up 11.3 percent on a reported basis from the prior-year quarter, while Drug Delivery Systems revenue reached EUR 123.2 million versus EUR 113.5 million a year earlier.

Profitability was more mixed. Q3 EBITDA amounted to EUR 75.0 million, producing a 26.8 percent margin compared with 32.3 percent in Q3 fiscal 2025. For the first nine months of fiscal 2026, EBITDA fell 3.8 percent year over year to EUR 205.3 million, while net income declined 9 percent to EUR 103.4 million.

Guidance points to a stronger finish

Yahoo Finance reports that SCHOTT Pharma confirmed fiscal 2026 revenue growth guidance of 5%-6% at constant currencies, raised from 2%-5%. The company also expects an EBITDA margin of 27%-28%, compared with its previous guidance of 27%, and said Q4 revenue growth should accelerate from the nine-month pace.

The main operational counterweight is the margin pressure in Drug Delivery Systems. Nine-month DDS EBITDA fell 16.3 percent to EUR 95.7 million, while the company cited lower utilization, infrastructure costs and a glass syringe impairment. Management expects a take-or-pay agreement with a major glass syringe customer to affect Q4 fiscal 2026 and future periods, according to Yahoo Finance.

JPMorgan sets EUR 27.10 target

JPMorgan initiated Schott Pharma at Overweight with a EUR 27.10 price target on September 15, 2026, as reported by FinanzNachrichten. The target is EUR 2.40 above the October 5 price, equivalent to 9.7 percent above it.

The stock's market value was EUR 3.7 billion on October 5, 2026. Its 52-week range was EUR 12.62 to EUR 25.60, placing the current price EUR 0.90 below the high. The company is scheduled to publish its fiscal 2026 results on December 10, 2026, according to finanzen.ch.

Stock remains below its yearly high

Schott Pharma was last at EUR 24.70 on Xetra on October 5, 2026, with the session high at EUR 24.90 and the session low at EUR 24.50. The price was EUR 0.90 below the 52-week high of EUR 25.60, keeping the next results release and the Q4 margin delivery as the clearest company-specific checkpoints.